Methamphetamine (METH) administration in mice, results in a chronic dopamine (DA) depletion associated with nerve terminal damage, with DA oxidation and generation of reactive oxygen species (ROS) primarily mediating this neurotoxicity. The oxidative stress induced by METH putatively activates nuclear enzyme poly(ADPribose) polymerase (PARP), with excessive PARP activation eventually leading to cell death. In this study, we show that prevention of PARP activation by treatment with FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], the compound that was recently identified as a novel PARP inhibitor (IC 50 for PARP-1 ϭ 33 nM, IC 50 for PARP-2 ϭ 7 nM), protects against both ROS-induced cells injury in vitro and METH-induced dopaminergic neuronal damage in an in vivo Parkinson's disease (PD) model. In PC12 cells, exposure of hydrogen peroxide or METH markedly induced PARP activation, and treatment with FR261529 (1 M) significantly reduced PARP activation and attenuated cell death. In the mouse METH model, METH (15 mg/ kg ϫ 2 i.p., 2 h apart) intoxication accelerated DA metabolism and oxidation in the striatum, with subsequent cell damage in nigrostriatal dopaminergic neurons after 4 days. Oral administration of FR261529 (10 or 32 mg/kg) attenuated the damage of dopaminergic neurons via marked reduction of PARP activity and not via changes in dopamine metabolism or body temperature. These findings indicate that the neuroprotective effects of a novel PARP inhibitor, FR261529, were accompanied by inhibition of METH-induced PARP activation, suggesting that METH induces nigrostriatal dopaminergic neurodegeneration involving PARP activation and also orally active and brainpenetrable PARP inhibitor FR261529 could be a novel attractive therapeutic candidate for neurodegenerative disorders such as PD.
with FR261529 (1 M) significantly reduced PARP activation and attenuated cell death. In the mouse METH model, METH (15 mg/ kg ϫ 2 i.p., 2 h apart) intoxication accelerated DA metabolism and oxidation in the striatum, with subsequent cell damage in nigrostriatal dopaminergic neurons after 4 days. Oral administration of FR261529 (10 or 32 mg/kg) attenuated the damage of dopaminergic neurons via marked reduction of PARP activity and not via changes in dopamine metabolism or body temperature. These findings indicate that the neuroprotective effects of a novel PARP inhibitor, FR261529, were accompanied by inhibition of METH-induced PARP activation, suggesting that METH induces nigrostriatal dopaminergic neurodegeneration involving PARP activation and also orally active and brainpenetrable PARP inhibitor FR261529 could be a novel attractive therapeutic candidate for neurodegenerative disorders such as PD.
Poly(ADP-ribose) polymerase (PARP) is activated after DNA damage that mediates neuronal cell death, providing a mechanism by which PARP inhibitors can exert neuroprotection. Reactive free radical species-mediated damage of DNA can activate PARP (Szabo et al., 1996; Eliasson et al., 1997) and consumes NAD and consequently ATP, culminating in cell dysfunction or necrosis (Ha and Snyder, 1999) . PARP also plays a central role in a caspase-independent apoptosis pathway mediated by apoptosis-inducing factor (Yu et al., 2002) . Translocation of plays a central role in a caspaseindependent apoptosis pathway mediated by apoptosis from the mitochondria to the nucleus is dependent on PARP activation in neurons treated with various DNA-damaging stimuli such as N-methyl-D-aspartate (NMDA) or hydrogen peroxide (Yu et al., 2002) . This cellular suicide mechanism of both necrosis and apoptosis by PARP activation has been implicated in the pathogenesis of brain injury and neurodegenerative disorders, and PARP inhibitors have been shown to be effective in animal models of stroke (Takahashi et al., 1999; Abdelkarim et al., 2001; Iwashita et al., 2004a) , traumatic brain injury (LaPlaca et al., 2001) , and Parkinson's disease (PD; Cosi et al., 1996; Iwashita et al., 2004b) .
Methamphetamine (METH) intoxication in mice produces neurodegeneration of dopaminergic terminals in the striatum and cell body loss in the substantia nigra pars compacta (SNpc) (Sonsalla et al., 1996; Hirata and Cadet, 1997; Kita et al., 1998) . METH enters nerve terminals via the dopamine transporter (DAT) and displaces both vesicular and intracellular dopamine (DA). This displacement results in increased DA release within the cytoplasm of DA terminals, with subsequent DA oxidation by monoamine oxidase (MAO) activity and auto-oxidation to reactive oxygen species (ROS) and H 2 O 2 (Cubells et al., 1994; Cadet and Brannock, 1998) . The role of oxidative stress in the neurochemical actions of METH is supported by the fact that METH can cause lipid and protein oxidation in mouse brain (Jayanthi et al., 1998; Gluck et al., 2001) and that the administration of antioxidants, such as ascorbate and vitamin E, can attenuate METHinduced toxicity (De Vito and Wagner, 1989) . Transgenic mice overexpressing the antioxidant enzyme copper/zinc superoxide dismutase showed an attenuated response to neurotoxic doses of METH (Cadet et al., 1994) .
METH administration can also lead to increased levels of extracellular glutamate (Nash and Yamamoto, 1992) , leading to excessive NMDA receptor activation and formation of superoxide and nitric oxide (Lafon-Cazal et al., 1993; Gunasekar et al., 1995) . Superoxide reacts with nitric oxide to produce peroxynitrite, a highly cytotoxic compound, that causes neuronal death in numerous models of brain damage, including cerebral ischemia and PD (Tabner et al., 2001) . Pharmacological inhibition of various neuronal nitric-oxide synthases (nNOS) reduces METH-induced neurotoxicity, and mice lacking the nNOS gene are resistant to this neurotoxicity (Di Monte et al., 1996; Itzhak et al., 1998) .
Changes in body temperature can also markedly influence the degree of METH neurotoxicity, with higher temperatures causing greater toxicity and lower temperatures affording neuroprotection (Bowyer et al., 1992; Albers and Sonsalla, 1995) . Furthermore, severe hyperthermia may result in the activation or up-regulation of proteins capable of oxidizing DA and formation of DA quinine (LaVoie and Hastings, 1999) . This evidence suggests that increased DA oxidation, generation of reactive species such as superoxide or peroxynitrite, as well as hyperthermia, are mediators of METH neurotoxicity.
Direct evidence for the involvement of PARP in the pathogenesis of METH-induced neurotoxicity comes from the evaluation of PARP inhibitors in mice. METH intoxication significantly reduced the levels of striatal dopamine in C57BL/6 mice, whereas treatment with the conventional PARP inhibitor benzamide ameliorated the depletion induced by METH (Cosi et al., 1996) . This led us to hypothesize that METH intoxication might induce nigrostriatal dopaminergic neurodegeneration in mice via PARP activation downstream of ROS generation and that PARP inhibition could ameliorate METH-induced neurotoxicity.
We have recently identified FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide; chemical structure shown in Fig.  1 ] as a novel and potent PARP inhibitor, by applying the rational discovery strategies, such as structure-based drug design, combinatorial chemistry, and conventional structureactivity relationship for improvement of potency. The purpose of the present study was, first, to investigate the PARPinhibiting activity and specificity of FR261529. The second purpose was to determine the PARP inhibitory properties and the neuroprotective properties of FR261529 in two in vitro experimental neuronal cell death models, in which PARP is markedly activated by H 2 O 2 or METH exposure. Finally, the neuroprotective properties of FR261529 and the effect of FR261529 on DA release, lipid peroxidation, and hyperthermia were evaluated in a mouse METH model, a relevant in vivo model of PD. 3-Aminobenzamide (3-AB) was also evaluated in this study as a reference PARP inhibitor.
Materials and Methods

Materials
Rat pheochromocytoma PC12 cells were purchased from American Type Culture Collection (Manassas, VA). FR261529 (chemical structure shown in Fig. 1 ) was synthesized at Fujisawa Pharmaceutical Co., Ltd. (Osaka, Japan). 3-AB was purchased from Sigma-Aldrich (St. Louis, MO). METH (methamphetamine hydrochloride) was purchased from Dainippon Pharmaceutical Co. Ltd. (Osaka, Japan). Tissue culture medium and fetal bovine serum were purchased from Sigma-Aldrich, and tissue culture dishes were from Sumitomo (Osaka, Japan). Hydrogen peroxide (30%) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) were from Wako Pure Chemicals (Tokyo, Japan). Recombinant human PARP enzyme was purchased from Trevigen (Gaithersburg, MD), and recombinant mouse PARP-2 enzyme was purchased from Alexis Biochemicals (San Diego, CA). Unless otherwise stated, all other materials were purchased from Sigma-Aldrich.
Measurement of PARP Inhibitory Activity in Vitro
To assess the PARP-1 or PARP-2 inhibitory activity of FR261529 and 3-AB, PARP activity was evaluated as described previously (Banasik et al., 1992) with minor modifications. PARP enzyme assay was carried out in a final volume of 100 l consisting of 50 mM Tris-HCl (pH 8.0), 25 mM MgCl 2 , 1 mM dithiothreitol, 10 g of activated salmon testes DNA, 0.1Ci of [adenylate- 32 P]NAD, 0.2 units of recombinant human PARP for PARP-1 assay or 0.1 units of recombinant mouse PARP-2 for PARP-2 assay, and various concentrations of FR261529 or 3-AB. The reaction mixture was incubated at room temperature (23°C) for 15 min, and the reaction was terminated by adding 200 l of ice-cold 20% trichloroacetic acid (TCA) and incubated at 4°C for 10 min. The precipitate was transferred onto GF/B filter (Packard Unifilter-GF/B) and washed three times with 10% TCA solution and 70% ethanol. After the filter was dried, the radioactivity was determined by liquid scintillation counting.
The nuclear extract was centrifuged at 11,000g for 10 min. The supernatant containing the proteins from the nuclear extract was removed carefully to a fresh tube. The protein was measured in the nuclear extract and then used for the PARP assay immediately.
For preparation of nuclear extracts from mouse brain, normal and/or drug-treated whole brains were dissected and transferred to a Teflon homogenizer. Buffer A was added at 300 mg of brain tissue per 1 ml and 10 strokes of homogenization were performed. The whole suspension was transferred equally to Eppendorf tubes followed by centrifugation in a microcentrifuge for 1 min. The supernatant containing mostly cytoplasmic constituents were removed, and 300 l of buffer B was added to the nuclear pellet in each of the Eppendorf tubes. The tubes were mixed thoroughly and placed on a microtube mixer for 15 min. The supernatant containing the proteins from the nuclear extract was removed carefully to a fresh tube. The protein was measured in the nuclear extract and then the crude solution containing PARP enzyme and DNA was used for the PARP assay immediately.
Specificity of FR261529
DAT Binding Assay. To determine the affinity of FR261529 and 3-AB to the DAT and also to evaluate the level of cell damage after METH intoxication in mice, the striatum and/or substantia nigra were dissected from mouse brains. Homogenate with KRH buffer containing 125 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO 4 , 1.3 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 5.6 mM glucose, 0.01 mM nialamide, and 25 mM HEPES, pH 7.4, was prepared by several centrifugations. For the DAT binding assay, mazindol binding to the DAT was evaluated according to the method of Javitch et al. (1984) with minor modifications. Binding was assayed by addition of membrane preparations from the striata or substantia nigra, about 125 g of protein, to an incubation solution (KRH buffer) containing 5 nM [ 3 H]mazindol (17 Ci/mmol; PerkinElmer Life and Analytical Sciences, Boston, MA) and 300 nM desipramine to occlude binding to the norepinephrine transporter. Samples in duplicate were incubated at 4°C for 1 h, and the reaction was stopped by addition of ice-cold KRH buffer. The reaction solution was rapidly filtered through Whatman GF/C filters and three washes with binding buffer using a cell harvester. Nonspecific binding was determined in the presence of 10 M cocaine.
Determination of [
3 H]Spiperone Binding Activity. The affinity of FR261529 and 3-AB to dopamine D2 receptor was measured by using a [ 3 H]spiperone binding assay as described previously (Zahniser and Dubocovich, 1983 ) with minor modifications. Briefly, the mice striatal membrane isolates (final 1 mg/ml) were incubated with 50 mM TrisHCl buffer (pH 7.4, containing 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , and 1 mM EDTA), different concentrations of drug, and 3 nM [ 3 H]spiperone (specific activity 107 Ci/mmol; Amersham Biosciences, Piscataway, NJ) for 45 min at 25°C and processed as described above. Nonspecific binding was determined in the presence of 10 M sulpiride.
Determination of MAO Inhibitory Activity. MAO activity in mouse brain was determined by radioassay as described by Wurtman and Axelrod (1963) with minor modifications, using [ 14 C]2-␤-ethyl-1-phenylethylamine HCl (about 50 mCi/mmol; PerkinElmer Life and Analytical Sciences) as substrates at concentrations of 20.8 M (specific activity 1.6 mCi/mmol). Briefly, mitochondria homogenate from mouse brain in 100 l of 67 mM sodium phosphate buffer, pH 7.4, was preincubated in 96-well plates at 37°C for 10 min. After the preincubation, [
14 C]2-␤-ethyl-1-phenylethylamine and different concentrations of FR261529 or 3-AB were added and incubated at 37°C for 20 min under gentle shaking. The reaction was terminated by placing the plate on wet ice and adding of cold 3 M HCl. The deaminated products were extracted by 0.5 ml of ethyl acetate, and the separation of the two phases was facilitated by centrifugation (7000g) at 15°C for 10 min. The samples were analyzed in the scintillation counter for the amount of 14 C in the upper phase. Determination of Radical Scavenging Activity and Lipid Peroxidation. To determine the radical scavenging activity of FR261529 and 3-AB and also for measurement of lipid peroxidation in the striatum after dosing of METH in mice, thiobarbituric acid reactive substances (TBARS) were used with the modified method of Buege and Aust (1978) and Callaway et al. (1998) . Briefly, mouse brain synaptosomes were prepared from C57/BL6 mice (Japan SLC, Shizuoka, Japan). To evaluate the inhibitory activity of FR261529 and 3-AB, different concentrations of each compound were dissolved 50% dimethyl sulfoxide and then 5 l was added to each rat brain synaptosome and incubated with ammonium ferric sulfate (100 M) at 37°C for 30 min. The reaction was stopped with addition of 20% TCA, and the precipitated proteins were removed by centrifugation at 10,000g for 15 min. The aliquots of supernatant were then added to an equal volume of thiobarbituric acid. The samples were heated at 95°C for 30 min and then cooled on ice before reading absorbance at 532 nm. Concentrations of TBARS were calculated using standard curve obtained with malondialdehyde (MDA). Percentage of inhibition of TBARS production was calculated as follows: 
Neuroprotective Efficacy in PC12 Cells
Determination of PARP Activation. To determine PARP activation directly in PC12 cells, PARP enzyme assay and NAD assay were used. PC12 cells were seeded at 2 ϫ 10 6 cells in an F75 culture flask and cultured for 24 h. Then, FR261529 was added to culture media at several concentrations. Thirty minutes later, cells were exposed H 2 O 2 (0.1-1 mM) or METH (0.1-1 mM) for 30 min, and cells were detached using cell scraper and then nuclear extracts were prepared as described above. PARP activation was determined by PARP enzyme assay using nuclear extracts as a mixture of PARP enzyme and nicked DNA. To determine NAD level, detached cells were collected in microcentrifuge tube by centrifugation for 5 min ϫ 100g at 4°C. Cell homogenate was extracted with 200 l of 0.5 M HClO 4 for 15 min and then 60 l of 2 M KOH/0.2 M K 2 HPO 4 -KH 2 PO 4 pH 7.5, was added to the acidic supernatant obtained by centrifugation. NAD level in the supernatant was measured using enzymatic conversion to NADH by alcohol dehydrogenase.
Assessment of Cytotoxicity. PC12 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal calf serum and a 1% (v/v) penicillin-streptomycin antibiotic mixture. Cells were grown in an atmosphere of 95% air and 5% CO 2 at 37°C for 24 h. For all experiments, cells were seeded at a density of 4 ϫ 10 4 cells/well in 96-well culture plates and allowed to attach overnight. The cells were incubated with or without hydrogen peroxide (0.1 mM) and FR261529 or 3-AB for 6 h. To evaluate cell survival, MTT assay was performed according to a minor modification of the standard method. Briefly, MTT was added to the cultures at a final concentration of 0.2 mg/ml and after incubation at 37°C for 2 h, the media were removed carefully and the reaction was stopped by addition of isopropanol containing 0.04 N HCl. The absorbance of each well was measured at 590 nm using a microplate reader (Molecular Devices, Sunnyvale, CA). In addition, hydrogen peroxideinduced cytotoxicity was quantified by a standard measurement of lactate dehydrogenase (LDH) release with the use of the LDH assay kit (Wako Pure Chemicals). Drug Treatment. FR261529 was dissolved in 100% dimethyl sulfoxide at 10 Ϫ2 M and 3-AB was dissolved in phosphate-buffered saline at 100 mM, and then both were diluted in DMEM without serum. These solutions were added to culture plate 0.5 h before H 2 O 2 exposure.
METH-Induced Parkinson's Model in Mice
Animals. For METH model, 9-to 10-week-old male C57/BL6 mice (Charles River, Hino, Japan) weighing 19 to 22 g were used. All animals were housed in a room maintained at 23 Ϯ 2°C with 55 Ϯ 5% humidity, and with a 12-h light/dark cycle (light on at 7:00 AM). The minimum quarantine period was at least 2 week before the experiment. Animals were housed five per cage and allowed free access to food and water. On the day of the experiment, mice were maintained in a room temperature of 23°C. Rectal temperatures were recorded immediately before the first administration of drug and every hour thereafter using a small-animal rectal probe (TERUMO-CTM-303; TERUMO, Tokyo, Japan). All experiments in the present study were performed under the guidelines of the Experimental Laboratory Animal Committee of Fujisawa Pharmaceutical Co. and were in strict accordance with the principles and guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize both the number of animals used and stress to the animals during experimental procedures.
Administration of METH and PARP inhibitors. To determine the neuroprotective properties of FR261529 and 3-AB in the mouse METH model, dose finding experiments of METH intoxication were conducted. Animals received 2 ϫ 10, 2 ϫ 15, 2 ϫ 25 or 4 ϫ 15 mg/kg of METH with i.p. injection at a 2h interval. FR261529 or 3-AB, which was suspended with 0.5% methylcellulose, was administered at doses of 3.2 to 32 mg/kg for FR261529 p.o. or 100 and 320 mg/kg for 3-AB i.p. twice at 1h prior to first injection of METH and then 4 h later. The administration volume was adjusted to 10 ml/kg in all experiments.
Preparation of Substantia Nigra and Striatum Homogenate. For PARP assay and DAT binding assay using tissue homogenates, whole brains were dissected and put on ice-cold brain slicer immediately. One-millimeter-thick slices, including SNpc and whole bilateral striata area, were sectioned precisely by referring to mouse brain map. The exact SNpc area was also confirmed by comparison with the result of TH immunostaining, and the TH-negative area was removed from the slice. The remaining tissues were used for preparation of the homogenate.
PARP Inhibition in Mouse Brain. To estimate the PARP inhibition by treatment of FR261529 in mice brain, FR261529 was administered in normal C57BL/6 mice at 3.2 to 32 mg/kg p.o. once, and each brain was dissected at two time points (1 and 4 h) after a single administration of FR261529. The brain homogenates were prepared immediately and PARP assay was conducted as described above.
Measurement of Striatal DA, DOPAC, HVA, and 3-MT Levels. The contents of DA, DOPAC, HVA, and 3-MT in the striatum were quantified using high-performance liquid chromatography with electrochemical detection. Four days after the drug administration, brains were quickly removed, and the striatum was dissected out on ice-cold dish. Samples were immediately frozen in liquid nitrogen and stored at Ϫ80°C until analysis. On the day of the assay, tissue samples were homogenized by Teflon homogenizer with 0.1 M perchloric acid and 0.1 mM EDTA-2Na containing 50 ng/ml isoproterenol as internal standard. After centrifugation (15,000g, 15min, 4°C), pH of supernatant from each sample was adjusted to 3.5 with sodium acetate. Adjusted supernatants were filtered and injected onto reversed phase catecholeamine column (SC-5ODS 3.0 ϫ 150 mm; Eicom Co., Ltd., Kyoto, Japan) with ECD-300 electrochemical detector (ϩ450 mV). The mobile phase consisted of 0.1 M sodium acetate buffer, 0.1 M citrate buffer, pH 3.5, 0.02 mM EDTA, 1 mM sodium octane sulfonic acid, and 15% methanol. The flow rate was maintained at 0.5 ml/min. DA and its metabolites were quantified by peak height comparisons with standards run on the day of analysis. To determine whether FR261529 and other drugs affect dopamine or its metabolites content, a single dose of FR261529 (32 mg/kg p.o.), nomifensine (3.2 mg/kg i.p.), haloperidol (3.2 mg/kg i.p.) or apomorphine (3.2 mg/kg i.p.) was administered, and the striatum was dissected after 1 h. The contents of DA, DOPAC, HVA, and 3-MT in the striatum were quantified as described above.
Pharmacokinetic Study in Mice. Measurement of the concentration of FR261529 in plasma and brain were performed in mice after p.o. administration at 32 mg/kg. FR261529 was suspended in 0.5% methylcellulose and administered orally in a volume of 10 ml/kg. The plasma and brain were collected at 0.5 and 2 h after the dosing, and the plasma and brain level of FR261529 were measured using high-performance liquid chromatography as described by Iwashita et al. (2004b) .
Statistical Analysis. The IC 50 values obtained from studies in vitro and in vivo were calculated using GraphPad Prism 3.3 software (GraphPad Software, Inc., San Diego, CA). All values are expressed as mean Ϯ S.E.M. Statistical significance of difference between groups was tested using one-way analysis of variance (ANOVA) followed by post hoc Dunnett's multiple comparison test. Comparison between two groups was conducted using two-tailed Student's t test. P values less than 0.05 were considered to be significant.
Results
PARP Inhibitory Activity of FR261529
To determine the species differences of PARP inhibitory activity of FR261529 and 3-AB, human recombinant PARP and nuclear extract from mouse brain were used. FR261529 potently inhibited the enzyme activity with an IC 50 value of 33 Ϯ 0.9 and 35 Ϯ 1.1 nM in human and mouse PARP, respectively (Table 1 ). The inhibitory activity of FR261529 was about 400-fold more potent than that of 3-AB (IC 50 values of 3-AB in this study were 11,200 Ϯ 810 and 11,800 Ϯ 690 nM in human and mouse PARP, respectively). To confirm the selectivity of FR261529 and 3-AB, PARP-2 enzyme assay PARP inhibitory activity of FR261529 and 3-AB were evaluated in human recombinant PARP and mouse PARP from nuclear extracts of mouse brain. IC 50 values were calculated from the concentration dependence of the inhibition curves by using computer-assisted nonlinear regression analyses. To determine pharmacological potential of FR261529 and 3-AB, D2 receptor binding assay, DAT binding assay, MAO assay, TBARS assay, and NOS assay were conducted. FR261529 and 3-AB did not exhibit D2 receptor affinities, DAT affinities, radical scavenging activity, MAO inhibitory activity, and NOS inhibitory activity at a concentration from 10 Ϫ8 to 10 Ϫ5 M in all assays, and all IC 50 values were under 10,000 nM. PARP inhibitory activities are means Ϯ S.E.M. of n ϭ 3 determinations tested in triplicate. was also conducted. In our assay system, FR261529 was shown to be about 5-fold more potent for PARP-2 (IC 50 value of 7 nM) than PARP-1 (IC 50 value of 33 nM), compared with conventional nonselective PARP inhibitor 3-AB (IC 50 value for PARP-1 ϭ 11.2 M and for PARP-2 ϭ 9.8 M).
Specificity of FR261529
A number of drugs that affect DA metabolism, the dopamine receptor, and dopamine transporter or generation of ROS or NO can prevent METH neurotoxicity. Therefore, to exclude the possibility that FR261529 could inhibit METH neurotoxicity directly, MAO-B inhibitory activity, DAT binding affinity, and D2 receptor binding affinity were evaluated. In the MAO-B assay, FR261529 (IC 50 value of Ͼ10,000 nM) did not affect deamination of the substrate 2-␤-ethyl-1-phenylethylamine in mouse brain homogenate, even with preincubation. Pargyline, which was used as a positive control, inhibited MAO-B activity with an IC 50 value of 146 nM. To determine the affinity of FR261529 to the dopamine transporter, a DAT binding assay was conducted using [
3 H]mazindol as a radioligand. In this assay, FR261529 did not inhibit mazindol binding to DAT, even at a concentration of 10 Ϫ5 M (IC 50 value of Ͼ10,000 nM), although nomifensine inhibited binding with an IC 50 value of 201 nM. Although apomorphine, a D2 agonist, inhibited spiperone binding with an IC 50 value of 201 nM, FR261529 showed no inhibitory activity even at 10 Ϫ5 M (IC 50 value of Ͼ10,000 nM). Radical scavenging activity and NOS inhibitory activity were evaluated using a TBARS assay and NOS catalytic activity assay, respectively. In TBARS assay, FR261529 did not inhibit TBARS production up to 10 Ϫ5 M (IC 50 value of Ͼ10,000 nM), although vitamin E showed radical scavenging activity with an IC 50 value of 228 nM. In the NOS assay, 7-nitroindazole, a selective nNOS inhibitor, prevented NOS catalytic activity assessed by [ 3 H]citrulline production with an IC 50 value of 319 nM, although FR261529 had no inhibitory activity up to 10 Ϫ5 M (IC 50 value of Ͼ10,000 nM). 3-AB also showed very low affinity to DAT and D2 receptor, and no inhibitory activity to MAO and NOS. Radical scavenging activity of 3-AB was not observed in the TBARS assay (Table 1) .
Neuroprotective Action in PC12 Cells
In this study, we first confirmed whether H 2 O 2 or METH treatment induced PARP activation and cell death in PC12 cells. PARP activation was confirmed by measurement of the amount of incorporation of 32 P-NAD polymer in PC12 cells. Exposure of 0.1 to 1 mM H 2 O 2 for 30 min markedly increased incorporation of 32 P-NAD polymer and treatment with FR261529 inhibited the PARP activation from a concentration of 10 Ϫ6 M (Fig. 2A) . METH treatment similarly induced formation of 32 P-NAD polymer in PC12 cells (Fig. 2B) . Treatment with FR261529 at concentrations higher than 10 Ϫ6 M significantly inhibited METH-induced PARP activation. PARP activation by H 2 O 2 exposure was also observed when assessed by NAD assay, and excessive PARP activation resulted in marked NAD depletion, and this NAD depletion was significantly inhibited by FR261529 treatment (Fig. 2C) . Exposure of 0.1 mM H 2 O 2 for 6 h induced severe cell damage, although FR261529 treatment at a concentration range from 10 Ϫ6 M significantly attenuated cell death as evaluated by MTT assay (Fig. 3A) and LDH assay (Fig. 3B) . A similar neuroprotective effect was observed in PC12 cells treated with 3-AB at concentrations higher than 10 Ϫ4 M (Fig. 3 , C and D).
Pharmacokinetic Study in Mice
The plasma and brain concentrations of FR261529 were determined at 0.5 and 2 h after oral administration at a dose of 32 mg/kg. Mean plasma and brain concentration was 2.98 6 cells in the nontreated control group). FR261529 at concentrations above 10 Ϫ6 M attenuated both H 2 O 2 -and METH-induced PARP activation, and at a 10 Ϫ5 M FR261529 prevented PARP activation completely (A and B). PARP activation was also confirmed by NAD depletion after H 2 O 2 (100 M) exposure. FR261529, at concentrations above 10 Ϫ6 M, attenuated H 2 O 2 -induced NAD depletion (C). Each point represents the mean Ϯ S.E.M. of at least three experiments. ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01 versus nontreated control group; and ##, P Ͻ 0.01 versus vehicle-treated control group (by one-way ANOVA followed by Dunnett's multiple comparison test). ###, P Ͻ 0.001 versus H 2 O 2 -treated control group (by Student's t test).
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at ASPET Journals on November 13, 2017 jpet.aspetjournals.org Downloaded from and 3.68 g/g at 0.5 h and 0.83 and 1.49 g/g at 2 h, respectively. Concentration of FR261529 in the brain was higher than that in the blood and the brain/plasma concentration ratio was 1.23 at C max time point (0.5 h after dosing) and 1.79 at 2 h after dosing.
Neuroprotective Action in Mouse METH Model
Neurotoxic Potential of METH. To determine a suitable dosing in the mouse METH model, the striatal content of DA was measured at 4 days after METH dosing. METH treatment (2 ϫ 10, 2 ϫ 15, 2 ϫ 25, or 4 ϫ 15 mg/kg, 2 h apart) caused significant and dose-dependent depletions in striatal DA by 30.6, 57.9, 79.7, and 90.6%, respectively, compared with the levels in saline-treated control (Table 2) . These dosing paradigms also decreased DAT binding sites by 29.2, 57.4, 75.2, and 88.3%, respectively (Table 2) . Changes in the striatal tissue levels of DA was coincident with the loss of striatal DAT binding sites and thus seems to represent the magnitude of dopaminergic terminal damage in the striatum. DAT binding sites in the SNpc was also measured after METH dosing. Four doses of METH treatments dose dependently decreased DAT binding sites, and the degree of depletion was significant at higher doses (Table 2 ). These findings indicate that the dosing of METH (2 ϫ 15 mg/kg, 2 h apart) produces moderate but significant dopaminergic neuronal damage and thus represents a suitable dosing paradigm to evaluate the potential of several compounds, including PARP inhibitors. In our preliminary studies, depletion of DA content in the striatum on day 4 after METH intoxication was comparable with that on day 14. Thus, the magnitude of dopaminergic terminals damage produced by METH could be stable even after 4 days. Therefore, the dosing paradigm and Comparison with dopamine content and DAT binding site in striatum following METH intoxication in mice. METH (2 ϫ 10, 2 ϫ 15, 2 ϫ 25, or 4 ϫ 15 mg/kg) was injected intraperitoneally at 2-h intervals, and dopamine content and DAT binding site in the striatum and DAT binding site in the SNpc were measured after 4 days. Both striatal dopamine content (14.21 Ϯ 0.40 ng/mg tissue in the nontreated control group) and DAT binding site (640 Ϯ 28.8 fmol/mg tissue in the nontreated control group) were significantly and dose-dependently decreased by METH treatment after 4 days. Decrease of dopamine content level was coincident with that of DAT binding site. DAT binding site in the SNpc (152 Ϯ 4.7 fmol/mg tissue in the nontreated control group) was also dose-dependently decreased by METH treatment, and at higher doses the depletion was statistically significant. Values are means Ϯ S.E.M. of n ϭ 5 to 6 mice.
Brain Area Assay
METH Dosing (i.p., 2-h interval) neurochemical measurement on day 4 were adopted for the subsequent drug studies. Brain PARP Inhibition by Treatment with FR261529. To explore the optimal dosing of FR261529 in mouse METH model, PARP inhibition by FR261529 treatment in mouse brain was determined by using PARP enzyme assay. FR261529 (3.2, 10, or 32 mg/kg) was orally administered in normal mice and nuclear extracts were prepared from mouse brain at 1 and 4 h after dosing. All doses of FR261529 significantly inhibited PAR polymer formation induced by addition of nicked DNA in the PARP enzyme assay at 1 h after dosing. Higher doses of FR261529 (10 and 32 mg/kg) moderately but still significantly inhibited PAR polymer formation at 4 h (Fig. 4) .
Neuroprotective Effects of FR261529 and 3-AB. FR261529 was administered to mice at doses of 3.2, 10, or 32 mg/kg p.o. twice (1 h before first and 1 h after second injection of METH), and the striatum was dissected 4 days later to quantify DA and its metabolites. In this paradigm, treatment of FR261529 prevented the depletion of striatal DA, DOPAC, and HVA content in a dose-dependent manner, and with statistically significant protection at higher doses (10 and 32 mg/kg; Fig. 5A ). 3-AB similarly significantly attenuated the depletion of DA and its metabolite contents at higher doses (320 mg/kg) (Fig. 5B) . Furthermore, treatment of FR261529 ameliorated the damage of the nigrostriatal dopaminergic terminals in the striatum, as assessed by DAT binding (Fig.  5C ). The depletion of DAT binding sites after METH intoxication and its percentage of recovery by FR261529 treatment was consistent with the degree of DA depletion and its recovery, respectively. PARP Activation and Inhibition by FR261529 in the SNpc. PARP activation in the SNpc was under the detectable level at 2, 4, and 8 h after METH intoxication (2 ϫ 15 mg/kg, 2 h apart), assessed by PAR polymer formation using nuclear extracts from mouse brain (data not shown). However, more severe dosing of METH (4 ϫ 15 mg/kg, 1 h apart) produced significant PARP activation in the SNpc 2 h after the last injection of METH. This PARP activation was significantly prevented by FR261529 treatment (2 ϫ 32 mg/kg, 5 h apart) as shown in Fig. 6 . METH-Induced Lipid Peroxidation. To determine the level of lipid peroxidation after METH intoxication, the amount of MDA, a lipid marker of oxidative stress, was measured in the striatum, hippocampus, and cortex using TBARS assay. METH treatment (2 ϫ 15 mg/kg, 2 h apart) resulted in regionally selective and time-dependent elevation of MDA. Elevation of MDA was detectable in the striatum at 2 h and persisted at 24 h after METH treatment (Fig. 7A) , but it was not observed in the hippocampus and cortex at both time points. Administration of DAT inhibitor nomifensine (3.2 mg/kg) and the DA antagonist haloperidol (3.2 mg/kg) significantly antagonized the elevation of MDA at 2 h after METH injections. On the other hand, the PARP inhibitors FR261529 and 3-AB did not prevent the elevation of MDA induced by METH treatment at neuroprotective doses (Fig. 7B) .
Effect on DA Metabolism in the Striatum. The efficacy of several drugs with protective effects against METH toxicity was analyzed by measuring DA and its metabolite contents 1 h after METH injection. Consistent with previous reports (Cosi et al., 1996; Fornai et al., 2001 ), administration of a DAT inhibitor (nomifensine, 3.2 mg/kg i.p.), a D2 receptor agonist (apomorphine, 3.2 mg/kg i.p.), or a D2 receptor antagonist (haloperidol, 3.2 mg/kg i.p.) affected DA and its metabolite contents at 1 h after dosing (Table 3 ). In contrast, FR261529 administration did not modify striatal DA, DOPAC, nor HVA levels (Table 4) .
Effects on Body Temperature. Rectal temperature was significantly elevated within 1 h after the first injection of METH (2 ϫ 15 mg/kg, 2 h apart) compared with the salinetreated control mice. This hyperthermia by METH was maintained until 3 h after the second injection of METH, and all doses of FR261529 (3.2, 10, and 32 mg/kg; twice, 4 h apart) did not induce a significant hypothermic effect (Fig. 8) .
Discussion
A novel PARP inhibitor FR261529, which was designed through a structure-based drug design system using the crystal structure of human recombinant PARP, showed potent inhibitory activity of both human recombinant PARP and PARP in murine nuclear extracts. Other newly synthesized quinoxaline derivatives also show no significant species difference between human PARP and mouse PARP inhibitory activity (data not shown), consistent with our previous data that quinazolinone derivatives showed no species differences on its inhibitory activity (Iwashita et al., 2004a,b) , as well as with reports that the PARP catalytic domain shows the highest degree of homology between different species (de Murcia et al., 1994) . Furthermore, more interestingly, FR261529 was more potent for PARP-2 than PARP-1 (5-fold higher selectivity) compared with nonselective general PARP inhibitors such as 3-AB, indicating that FR261529 and its derivatives could be the first class of PARP inhibitors that have some degree of selectivity for PARP-2 among several published PARP inhibitors (unpublished data). However, further Normal mice treated with 3.2, 10, or 32 mg//kg FR261529 were decapitated after 1 and 4 h, and nuclear extracts containing PARP enzyme and drug were prepared for in vitro PARP assay to evaluate the PARP inhibition level by FR261529. At 1 h after treatment of FR261529, all doses of this compound significantly inhibited PARP activation induced by addition of nicked-DNA in an in vitro assay system. At 4 h, only the higher dose of FR261529 (10 and 32 mg/kg) slightly but significantly inhibited PARP activation in this assay system. PARP activations represent the incorporation of 32 P-NAD polymer (8230 Ϯ 339 cpm/10 mg of brain tissue in the nontreated control group). Values are means Ϯ S.E.M. of n ϭ 6 to 7 mice. ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01 versus vehicle-treated control group (by one-way ANOVA followed by Dunnett's multiple comparison test). METH enters DA terminals via the DAT and displaces both vesicular and intracellular DA. This results in increased DA release within the cytoplasm of DA terminals, where DA is oxidized by MAO activity and auto-oxidation to ROS and hydrogen peroxide (Cubells et al., 1994; Cadet and Brannock, 1998) . METH administration can also lead to increased extracellular glutamate (Nash and Yamamoto, 1992) , which, in turn, induces NMDA receptor activation, linking to the formation of superoxide and nitric oxide (Lafon-Cazal et al., 1993; Gunasekar et al., 1995; Yamamoto and Zhu, 1998) . Superoxide may react with nitric oxide produced by NOS to form the potent oxidant peroxynitrite, which damages intra- (15 mg/kg, 2 h apart) and drug (twice at 1 h before first injection of METH and then 4 h later) paradigms were developed. The striatum was dissected from each mouse at 4 days after METH administration. In the nontreated control group, the contents of DA, DOPAC, and HVA were 13.97 Ϯ 0.18, 0.82 Ϯ 0.03, and 1.41 Ϯ 0.05 ng/mg tissue, respectively. A, treatment of FR261529 dose dependently attenuated the depletion of striatal DA, DOPAC, and HVA contents, and its effect was statistically significant at higher doses (10 and 32 mg/kg). B, administration of 3-AB partially prevented the depletion of DA, DOPAC, and HVA contents in the striatum, and its effect was statistically significant. C, FR261529 treatment also attenuated the depletion of DAT binding sites in the striatum, and its effects were dose-dependent and significant at higher doses (10 and 32 mg/kg). Data represent the percentage of the nontreated control group (683 Ϯ 16.4 fmol/mg tissue). Values are means Ϯ S.E.M of n ϭ 6 to 7 mice. Significant difference from control value are indicated by ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01 versus vehicletreated control group (by one-way ANOVA followed by Dunnett's multiple comparison test), and by ##, P Ͻ 0.01 versus vehicle-treated control group (by Student's t test).
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at ASPET Journals on November 13, 2017 jpet.aspetjournals.org cellular proteins and DNA to cause cell death. Although PARP is activated after DNA damage that mediates neuronal cell death, providing a mechanism by which PARP inhibitor such as benzamide can exert neuroprotection against METH toxicity (Cosi et al., 1996) , drugs that affect DA release and metabolism can also block METH-induced cell death. To differentiate between these mechanisms, we determined whether neuroprotection of FR261529 is achieved by inhibition of binding to DA receptor, binding to DAT, and MAO activity. FR261529 has no inhibitory potential against these activities, suggesting that FR261529 is not able to affect DA uptake or inhibit accelerated DA metabolism.
The role of NOS in METH-induced dopaminergic neurotoxicity, neuroprotection by various nNOS inhibitors, along with the evidence that mice lacking the nNOS gene are resistant to METH-induced dopaminergic neurotoxicity have been reported (Di Monte et al., 1996; Itzhak et al., 1998) . Furthermore, the administration of antioxidants can attenuate METH-induced neurotoxicity (De Vito and Wagner, 1989) , and transgenic mice overexpressing the antioxidant enzyme copper/zinc superoxide dismutase showed an attenuated response to neurotoxic doses of METH (Cadet et al., 1994) . These results indicate that radical scavengers and nNOS inhibitors can block METH-induced dopaminergic neuron damage. FR261529 had no antioxidant properties or nNOS inhibitory activity, even at a concentration of 10 Ϫ5 M, suggesting that neither radical scavenging activity nor nNOS inhibition is involved in the action of FR261529. Although the effects of FR261529 on other diverse classes of known neurotransmitter receptors, ion channels, or enzymes have not been fully clarified, the neuroprotective properties are likely the consequence of its specific PARP inhibitory activity.
To determine PARP inhibitory and neuroprotective properties of FR261529 in cultured cells, PARP activation and cell damage were induced by H 2 O 2 or METH exposure in PC12 cells. In this cell death system, H 2 O 2 exposure markedly induced PARP activation, concomitant NAD depletion, and early stage cell death. Inconsistent with the potent PARP inhibitory activity of FR261529 (IC 50 ϭ 33 nM), this compound attenuated both PARP activation and cell death at a concentration higher than 1000 nM (30-fold difference), suggesting that FR261529 does not have good cell permeability compared with that of 3-AB, another widely used PARP inhibitor (IC 50 ϭ 11.2 M versus minimum effective concentration ϭ 100 M; Ͻ10-fold difference) and quinoxaline derivatives (Ͻ10-fold difference; data not shown). Other quinoxaline derivatives of FR261529 also showed a discrepancy between PARP inhibitory activity in enzyme assay and neuroprotective properties in cultured cells (data not shown). Therefore, we speculate that the relatively low potency of neuroprotective properties of FR261529 and its derivatives in mouse METH model results from, in part, its poor permeability across the cell membrane.
METH-induced dopaminergic neuronal damage, assessed by DA and metabolite contents, was well correlated with the reduction of DAT binding sites in the striatum. Although the reduction of DAT binding sites in the SNpc was relatively . METH-induced lipid peroxidation in the striatum. The degree of lipid peroxidation following METH treatment was measured using by TBARS assay. A, METH treatment (2 ϫ 15 mg/kg, 2 h apart) time dependently increased the generation of MDA in the striatum specifically, and its effect persisted on until 24 h after last METH treatment. B, administration of nomifensine or haloperidol, which has protective potential in mouse METH model, significantly attenuated the MDA production at 2 h after METH treatment. However, neuroprotective dose of 3-AB or FR261529 did not show any change of MDA production. Data are presented as mean Ϯ S.E.M of five to six mice. Significant difference from control value is indicated by ‫,ءء‬ P Ͻ 0.01, statistically significant compared with control group (by Student's t test). small compared with that in the striatum, a good correlation was also observed between the depletion of DAT binding sites in the striatum and SNpc. In our preliminary study, we confirmed that the reduction of TH-positive neurons in the SNpc correlated with the decrease in DA contents in the striatum. These results support the notion that the depletion of DAT binding sites is consistent with damage in the striatum and the loss of cell bodies in the SNpc and that the DAT binding assay is a suitable substitute for quantifying the dopaminergic cell death with TH immunostaining.
The most important finding in the present study was that the treatment of FR261529 after METH intoxication dose dependently ameliorated the depletion of DA and its metabolites, as well as that of DAT binding sites in the striatum. FR261529 was orally active, with a brain concentration of FR261529 (32 mg/kg p.o.) of 1.49 g/g, which is estimated as higher than 10 Ϫ6 M, at 2 h postdosing. Thus, this dosing regimen yielded sufficient brain levels of FR261529 to exert PARP inhibitory activity. Although FR261529 attenuated the depletion of DAT binding sites in the SNpc, the amelioration was not statistically significant because of the small reduction by METH treatment (DAT binding site in the SNpc was 85.8% for vehicle control and 91.1% for FR261529 treatment compared with normal; data not shown). Consistent with these data, METH-induced PARP activation in the SNpc was undetectable after two dosings of METH. However, four doses of METH induced PARP activation at a detectable level, and the neuroprotective dose of FR261529 significantly inhibited PARP activation, supporting our view that METH neurotoxicity leads to PARP activation and that the neuroprotective properties of FR261529 involve specific PARP inhibitory activity.
The role of oxidative stress in the biochemical actions of METH is supported by the fact that METH can cause lipid and protein oxidation in brain (Jayanthi et al., 1998; Gluck et al., 2001) , and the administration of antioxidants attenuates METH-induced toxicity (De Vito and Wagner, 1989) . Furthermore, drugs that inhibit lipid peroxidation are neuroroprotective against METH neurotoxicity in the striatum (Cadet et al., 1994) . In the present study, METH-induced lipid peroxidation in the striatum was observed at 2 h after METH treatment, and drugs that are neuroprotective against METH neurotoxicity, such as the DAT inhibitor nomifensine and the D2 receptor antagonist haloperidol, effectively attenuated the production of MDA. However, the PARP inhibitors 3-AB and FR261529, at neuroprotective doses, had no influ- Fig. 8 . Effect of FR261529 on body temperature during METH treatment in mice. METH-induced hyperthermia was observed immediately after first injection of METH treatment (2 ϫ 15 mg/kg, 2 h apart) and persisted on 4 h later. Treatment of FR261529 at doses from 3.2 to 32 mg/kg did not show hypothermic action and did not affect hyperthermia of METH treatment. Data are presented as mean Ϯ S.E.M of five to six mice. Significant difference from normal group are indicated by ‫,ءء‬ P Ͻ 0.01 (by Student's t test). These drugs affected the DA and its metabolite contents at 1 h after dosing in normal mice; however, FR261529 even at a neuroprotective dose in mouse METH model did not modify striatal DA and its metabolites DOPAC, HVA, and 3-MT levels, compared with vehicle-treated mice. In the nontreated control group, the concentrations of DA and its metabolites DOPAC, HVA, and 3-MT were 14.17 Ϯ 0.39, 0.84 Ϯ 0.02, 1.40 Ϯ 0.03, and 0.25 Ϯ 0.02, respectively. Data are presented as mean Ϯ S.E.M. of 5 to 6 mice.
Drug
Route DA DOPAC HVA 3-MT mg/kg ence on MDA generation after METH treatment. These results offer supportive evidence that METH produces oxidative damage in vivo but that FR261529 does not inhibit the generation of METH-induced radical formation. Body temperature has also been found to markedly influence METH-induced DA neurotoxicity. METH-induced formation of ROS is temperature-sensitive and is attenuated by hypothermia (Bowyer et al., 1992; Ali et al., 1994) . These findings suggest that hyperthermia facilitates formation of oxidative species resulting from the administration of highdose METH treatment, whereas hypothermia is neuroprotective. Severe hyperthermia may result in the activation or up-regulation of proteins capable of oxidizing DA and formation of DA quinine (LaVoie and Hastings, 1999) . In this study, FR261529 did not affect METH-induced hyperthermia or METH-induced lipid peroxidation in the striatum, providing evidence that neuroprotective effect of FR261529 is not due to inhibition of SOD and/or NO production directly.
In conclusion, a newly synthesized PARP inhibitor, FR261529, exhibited potent PARP inhibition both in in vitro and in vivo, with significant neuroprotective activity after METH intoxication in mice, suggesting that nigro-striatal dopaminergic neurodegeneration induced by METH involves PARP activation and therefore this METH model might be a useful neurodegenerative model in experimental animals to evaluate neuroprotective properties of PARP inhibitors. Furthermore, the orally active and brain penetrable PARP inhibitor FR261529, or one of its derivatives, could be not only an important tool for investigating the physiological role of PARP in neurodegenerative pathways but also an attractive therapeutic candidate for neurodegenerative disorders such as Parkinson's disease.
